JG
VRTX icon

Jefferies Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Jefferies Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1.51M Hold
5,200
– – 0.01% 692
2022
Q2 		$1.47M Sell
5,200
-9,200
-64% -$2.46M 0.01% 695
2022
Q1 		$3.76M Sell
14,400
-65,600
-82% -$15.6M 0.02% 489
2021
Q4 		$17.6M Buy
80,000
+20,000
+33% +$3.89M 0.1% 159
2021
Q3 		$10.9M Buy
+60,000
New +$11.7M 0.08% 236
2021
Q2 		– Sell
-3,000
Closed -$645K – 2022
2021
Q1 		$645K Sell
3,000
-2,000
-40% -$439K 0.01% 1051
2020
Q4 		$1.18M Buy
+5,000
New +$1.15M 0.01% 882
2020
Q2 		– Sell
-15,100
Closed -$3.59M – 2075
2020
Q1 		$3.59M Buy
15,100
+8,500
+129% +$1.95M 0.04% 433
2019
Q4 		$1.45M Buy
6,600
+5,900
+843% +$1.19M 0.01% 1243
2019
Q3 		$119K Buy
+700
New +$124K ﹤0.01% 2471
2019
Q1 		– Sell
-26,400
Closed -$4.38M – 2663
2018
Q4 		$4.38M Buy
+26,400
New +$4.57M 0.04% 478
2018
Q1 		– Sell
-3,900
Closed -$584K – 2745
2017
Q4 		$584K Sell
3,900
-13,600
-78% -$2.01M ﹤0.01% 1654
2017
Q3 		$2.66M Sell
17,500
-7,300
-29% -$1.1M 0.02% 803
2017
Q2 		$3.2M Buy
24,800
+3,600
+17% +$433K 0.02% 741
2017
Q1 		$2.32M Buy
+21,200
New +$1.87M 0.02% 833
2015
Q3 		– Sell
-16,900
Closed -$2.09M – 3078
2015
Q2 		$2.09M Sell
16,900
-18,100
-52% -$2.28M 0.01% 891
2015
Q1 		$4.13M Sell
35,000
-75,000
-68% -$8.99M 0.02% 486
2014
Q4 		$13.1M Buy
+110,000
New +$12.4M 0.08% 218
2014
Q3 		– Sell
-49,700
Closed -$4.71M – 2470
2014
Q2 		$4.71M Buy
49,700
+29,900
+151% +$2.1M 0.04% 366
2014
Q1 		$1.4M Sell
19,800
-4,700
-19% -$372K 0.01% 758
2013
Q4 		$1.82M Buy
+24,500
New +$1.71M 0.01% 608

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jefferies Group's VRTX Position: Q3 2022 in Review

Jefferies Group increased its Vertex Pharmaceuticals (VRTX) stake by 30% in Q3 2022, buying an estimated $95.2K and bringing the position to 1,447 shares worth $419K. The position accounts for ﹤0.01% of the portfolio, ranked #1098.

Jefferies Group first reported a position in VRTX in Q2 2013 and has held it in 35 quarters since. The position peaked at $15.4M in Q4 2014. 1,124 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

  • Jefferies Group held 1,447 shares of Vertex Pharmaceuticals worth $419K as of Q3 2022.
  • Jefferies Group bought 331 Vertex Pharmaceuticals shares in Q3 2022, an estimated $95.2K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1098 holding.
  • Jefferies Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 35 quarters since.
  • Jefferies Group's Vertex Pharmaceuticals position peaked at $15.4M in Q4 2014.
  • 1,124 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.